Denali Therapeutics (DNLI) Stock Forecast & Price Target

Denali Therapeutics is positioned favorably because its TV/TfR platform directly addresses one of biotech’s hardest problems: delivering therapeutics across the BBB into the CNS, while also enabling systemic control in well-validated targets where monitoring and dosing are more practical. The commercial launch of AVLAYAH has already shown strong traction, with 3Q26 net product revenue of $17.8M, a beat versus expectations and management guiding 4Q26 to $30.0M to $32.0M as coverage exceeds 70% of U.S. lives and 20 state Medicaid programs support access. Fundamentally, the company combines a broad, differentiated CNS pipeline with about $1.0B in cash, a recent PRV gain, and multiple data catalysts expected in 2027 that could further validate both the platform and its programs.

Denali Therapeutics is facing meaningful regulatory risk because its reliance on accelerated review paths leaves approval vulnerable to requests for additional data, changed requirements, or longer studies that could delay or derail commercialization. The company’s outlook is also weakened by the possibility that approved products may not receive labels with the necessary features to gain traction in the market, limiting commercial adoption even if development succeeds. On the financial side, the company will likely need to access the capital markets to fund ongoing development, and any failure to raise capital could constrain its ability to complete programs on time and increase dilution risk.